medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-9-12-16medalphabet-3763Research ArticleСтатьиОбзор современных методов лечения витилигоReview of modern methods of treating vitiligohttps://orcid.org/0009-0007-7952-0162БаженоваЕ. В.BazhenovaE. V.

Баженова Елизавета Валерьевна - врач-ординатор, кафедра дерматовенерологии и косметологии.

Москва

Elizaveta V. Bazhenova - resident physician at Dept of Dermatovenerology and Cosmetology.

Moscow

https://orcid.org/0000-0002-3190-7460КругловаМ. С.KruglovaM. S.

Круглова Мария Сергеевна - студентка 3 курса лечебного факультета.

Москва

Maria S. Kruglova - 3rd year student of the Faculty of Medicine.

Moscow

kruglovamashulka@gmail.comФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РоссииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation20242007202409Дерматология (1)1216Copyright © Баженова Е.В., Круглова М.С., 20242024Баженова Е.В., Круглова М.С.Bazhenova E.V., Kruglova M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3763

Витилиго – аутоиммунное заболевание, вызывающее депигментацию кожи. Статья представляет собой обзор литературы с подробным описанием патогенеза и основными комбинациями терапевтических подходов. Затронут вопрос использования пероральных и топических ингибиторов янус-киназ для лечения витилиго.

Vitiligo is an autoimmune disease that causes skin depigmentation. The article is a review of the literature with a detailed description of the pathogenesis and the main combinations of therapeutic approaches. The issue of the use of oral and topical janus kinase inhibitors for the treatment of vitiligo was raised.

витилигодепигментацияпатогенез витилиготерапия витилигофототерапияингибиторы янус-киназJAK/STATруксолитинибоксидативный стрессCXCL9CXCL10vitiligodepigmentationvitiligo pathogenesisvitiligo therapyphototherapyjanus kinase inhibitorsJAK/STATruxolitiniboxidative stressCXCL9CXCL10ReferencesAli Alikhan; Lesley M. Felsten; Meaghan Daly; Vesna Petronic-Rosic (2011). Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. 65 (3), 0–491.Ali Alikhan; Lesley M. Felsten; Meaghan Daly; Vesna Petronic-Rosic (2011). Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. 65 (3), 0–491.Kundu R. V., Mhlaba J. M., Rangel S. M., Le Poole I. C. The convergence theory for vitiligo: A reappraisal. Exp Dermatol. 2019 Jun; 28 (6): 647–655.Kundu R. V., Mhlaba J. M., Rangel S. M., Le Poole I. C. The convergence theory for vitiligo: A reappraisal. Exp Dermatol. 2019 Jun; 28 (6): 647–655.Wagner R.Y., Luciani F., Cario-André M., Rubod A., Petit V., Benzekri L., Ezzedine K., Lepreux S., Steingrimsson E., Taieb A., Gauthier Y., Larue L., Delmas V. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol. 2015 Jul; 135 (7): 1810–1819.Wagner R.Y., Luciani F., Cario-André M., Rubod A., Petit V., Benzekri L., Ezzedine K., Lepreux S., Steingrimsson E., Taieb A., Gauthier Y., Larue L., Delmas V. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol. 2015 Jul; 135 (7): 1810–1819.Boukhedouni N., Martins C., Darrigade A.S., Drullion C., Rambert J., Barrault C., Garnier J., Jacquemin C., Thiolat D., Lucchese F., Morel F., Ezzedine K., Taieb A., Bernard F.X., Seneschal J., Boniface K. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020 Jun 4;5 (11): e133772.Boukhedouni N., Martins C., Darrigade A.S., Drullion C., Rambert J., Barrault C., Garnier J., Jacquemin C., Thiolat D., Lucchese F., Morel F., Ezzedine K., Taieb A., Bernard F.X., Seneschal J., Boniface K. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020 Jun 4;5 (11): e133772.Liu H., Wang Y., Le Q., Tong J., Wang H. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2023 Nov 8: e2250281.Liu H., Wang Y., Le Q., Tong J., Wang H. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2023 Nov 8: e2250281.Shah F, Giri PS, Bharti AH, Dwivedi M. Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients. Exp Dermatol. 2024 Jan;33(1): e14982.Shah F, Giri PS, Bharti AH, Dwivedi M. Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients. Exp Dermatol. 2024 Jan;33(1): e14982.Jin Y., Andersen G., Yorgov D., Ferrara T.M., Ben S., Brownson K.M., Holland P.J., Birlea S.A., Siebert J., Hartmann A., et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 2016; 48: 1418–1424.Jin Y., Andersen G., Yorgov D., Ferrara T.M., Ben S., Brownson K.M., Holland P.J., Birlea S.A., Siebert J., Hartmann A., et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 2016; 48: 1418–1424.Quan C., Ren Y.Q., Xiang L.H., Sun L.D., Xu A.E., Gao X.-H., Chen H.-D., Pu X.-M., Wu R.-N., Liang C.-Z., et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat. Genet. 2010; 42: 614–618.Quan C., Ren Y.Q., Xiang L.H., Sun L.D., Xu A.E., Gao X.-H., Chen H.-D., Pu X.-M., Wu R.-N., Liang C.-Z., et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat. Genet. 2010; 42: 614–618.Jin Y., Birlea S.A., Fain P.R., Ferrara T.M., Bem S., Riccardi S.L., Cole J.B., Gowan K., Holland P.J., Bennett D.C., et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat. Genet. 2012; 44: 676–680.Jin Y., Birlea S.A., Fain P.R., Ferrara T.M., Bem S., Riccardi S.L., Cole J.B., Gowan K., Holland P.J., Bennett D.C., et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat. Genet. 2012; 44: 676–680.Tang X. F., Zhang Z., Hu D. Y., Xu A. E., Zhou H. S., Sun L. D., Gao M., Gao T.-W., Gao X.-H., Chen H.-D., et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J. Investig. Dermatol. 2013; 133: 403–410.Tang X. F., Zhang Z., Hu D. Y., Xu A. E., Zhou H. S., Sun L. D., Gao M., Gao T.-W., Gao X.-H., Chen H.-D., et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J. Investig. Dermatol. 2013; 133: 403–410.Jin Y, Birlea S.A., Fain P.R., Gowan K., Riccardi S.L., Holland P.J., Mailloux C.M., Sufit A. J., Hutton S. M., Amadi-Myers A., Bennett D. C., Wallace M. R., McCormack W.T., Kemp E. H., Gawkrodger D. J., Weetman A. P., Picardo M., Leone G., Taïeb A., Jouary T., Ezzedine K., van Geel N., Lambert J., Overbeck A., Spritz R.A. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010 May 6;362(18):1686–97.Jin Y, Birlea S.A., Fain P.R., Gowan K., Riccardi S.L., Holland P.J., Mailloux C.M., Sufit A. J., Hutton S. M., Amadi-Myers A., Bennett D. C., Wallace M. R., McCormack W.T., Kemp E. H., Gawkrodger D. J., Weetman A. P., Picardo M., Leone G., Taïeb A., Jouary T., Ezzedine K., van Geel N., Lambert J., Overbeck A., Spritz R.A. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010 May 6;362(18):1686–97.Jian Z., Li K., Song P., Zhu G., Zhu L., Cui T., Liu B., Tang L., Wang X., Wang G., et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: A possible mechanism for melanocyte degeneration in vitiligo. J. Investig. Dermatol. 2014; 134: 2221–2230.Jian Z., Li K., Song P., Zhu G., Zhu L., Cui T., Liu B., Tang L., Wang X., Wang G., et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: A possible mechanism for melanocyte degeneration in vitiligo. J. Investig. Dermatol. 2014; 134: 2221–2230.Sravani P. V., Babu N. K., Gopal K. V.T., Rao G. R.R., Rao A. R., Moorthy B., Rao T. R. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J. Dermatol. Venereol. Leprol. 2009; 75: 268–271.Sravani P. V., Babu N. K., Gopal K. V.T., Rao G. R.R., Rao A. R., Moorthy B., Rao T. R. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J. Dermatol. Venereol. Leprol. 2009; 75: 268–271.Ozturk I.C., Batcioglu K., Karatas F., Hazneci E., Genc M. Comparison of plasma malondialdehyde, glutathione, glutathione peroxidase, hydroxyproline and selenium levels in patients with vitiligo and healthy controls. Indian J. Dermatol. 2008; 53: 106–110.Ozturk I.C., Batcioglu K., Karatas F., Hazneci E., Genc M. Comparison of plasma malondialdehyde, glutathione, glutathione peroxidase, hydroxyproline and selenium levels in patients with vitiligo and healthy controls. Indian J. Dermatol. 2008; 53: 106–110.Xuan Y., Yang Y., Xiang L., Zhang C. The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death. Oxid. Med. Cell. Longev. 2022; 2022: 8498472. doi: 10.1155/2022/8498472.Xuan Y., Yang Y., Xiang L., Zhang C. The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death. Oxid. Med. Cell. Longev. 2022; 2022: 8498472. doi: 10.1155/2022/8498472.Toosi S., Orlow S. J., Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012 Nov;132(11):2601–9.Toosi S., Orlow S. J., Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012 Nov;132(11):2601–9.Chivukula N., Ramesh K., Subbaroyan A., Sahoo A.K., Dhanakoti G.B., Ravichandran J., Samal A. ViCEKb: Vitiligo-linked Chemical Exposome Knowledgebase. Sci Total Environ. 2024 Feb 25; 913: 169711.Chivukula N., Ramesh K., Subbaroyan A., Sahoo A.K., Dhanakoti G.B., Ravichandran J., Samal A. ViCEKb: Vitiligo-linked Chemical Exposome Knowledgebase. Sci Total Environ. 2024 Feb 25; 913: 169711.Lee E.J., Kim J.Y., Yeo J.H., Park S., Bae Y.J., Kwon I.J., Seong S.H., Lee J., Oh SH. ISG15-USP18 Dysregulation by Oxidative Stress Promotes IFN-γ Secretion from CD 8+ T Cells in Vitiligo. J Invest Dermatol. 2024 Feb;144(2):273–283.e11.Lee E.J., Kim J.Y., Yeo J.H., Park S., Bae Y.J., Kwon I.J., Seong S.H., Lee J., Oh SH. ISG15-USP18 Dysregulation by Oxidative Stress Promotes IFN-γ Secretion from CD 8+ T Cells in Vitiligo. J Invest Dermatol. 2024 Feb;144(2):273–283.e11.Kang P., Zhang W., Chen X., Yi X., Song P., Chang Y., Zhang S., Gao T., Li C., Li S. TRPM2 mediates mitochondria-dependent apoptosis of melanocytes under oxidative stress. Free Radic. Biol. Med. 2018; 126: 259–268.Kang P., Zhang W., Chen X., Yi X., Song P., Chang Y., Zhang S., Gao T., Li C., Li S. TRPM2 mediates mitochondria-dependent apoptosis of melanocytes under oxidative stress. Free Radic. Biol. Med. 2018; 126: 259–268.Lazarova R., Hristakieva E., Lazarov N., Shani J. Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol Biochem. 2000 Jul; 108 (3): 262–7.Lazarova R., Hristakieva E., Lazarov N., Shani J. Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol Biochem. 2000 Jul; 108 (3): 262–7.Schallreuter K.U., Wood J.M., Ziegler I., Lemke K.R., Pittelkow M.R., Lindsey N.J., Gütlich M. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta. 1994 May 25; 1226 (2): 181–92.Schallreuter K.U., Wood J.M., Ziegler I., Lemke K.R., Pittelkow M.R., Lindsey N.J., Gütlich M. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta. 1994 May 25; 1226 (2): 181–92.Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов» Клинические рекомендации: Витилиго – 2023.All-Russian public organization “Russian Society of Dermatovenerologists and Cosmetologists” Clinical recommendations: Vitiligo – 2023. (In Russ.)Ezzedine K., Eleftheriadou V., Jones H., Bibeau K., Kuo F. I., Sturm D., Pandya A.G. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021 Nov; 22 (6): 757–774.Ezzedine K., Eleftheriadou V., Jones H., Bibeau K., Kuo F. I., Sturm D., Pandya A.G. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021 Nov; 22 (6): 757–774.Chang Y, Zhang S, Zhang W, Li S, Li C. The Efficacy and Psychoneuroimmunology Mechanism of Camouflage Combined With Psychotherapy in Vitiligo Treatment. Front Med (Lausanne). 2022 May 27; 9: 818543.Chang Y, Zhang S, Zhang W, Li S, Li C. The Efficacy and Psychoneuroimmunology Mechanism of Camouflage Combined With Psychotherapy in Vitiligo Treatment. Front Med (Lausanne). 2022 May 27; 9: 818543.Seneschal J., Speeckaert R., Taïeb A., Wolkerstorfer A., Passeron T., Pandya A.G., et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force – Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023; 37: 2185–2195.Seneschal J., Speeckaert R., Taïeb A., Wolkerstorfer A., Passeron T., Pandya A.G., et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force – Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023; 37: 2185–2195.Alshiyab D., Ba-Shammakh S.A., Al-Fakih A., Tashman O., Sarakbi D., Al-Qarqaz F., Muhaidat J., Atwan A., Cork M. J. Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial. J Dermatolog Treat. 2024 Dec; 35 (1): 2296851.Alshiyab D., Ba-Shammakh S.A., Al-Fakih A., Tashman O., Sarakbi D., Al-Qarqaz F., Muhaidat J., Atwan A., Cork M. J. Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial. J Dermatolog Treat. 2024 Dec; 35 (1): 2296851.Rosmarin D., Passeron T., Pandya A.G., Grimes P., Harris J.E., Desai S.R., Lebwohl M., Ruer-Mulard M., Seneschal J., Wolkerstorfer A., Kornacki D., Sun K., Butler K., Ezzedine K.; TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20; 387 (16): 1445–1455.Rosmarin D., Passeron T., Pandya A.G., Grimes P., Harris J.E., Desai S.R., Lebwohl M., Ruer-Mulard M., Seneschal J., Wolkerstorfer A., Kornacki D., Sun K., Butler K., Ezzedine K.; TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20; 387 (16): 1445–1455.Hu W., Thornton M., Livingston R.A. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. Am J Clin Dermatol. 2024 Mar; 25 (2): 327–332.Hu W., Thornton M., Livingston R.A. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. Am J Clin Dermatol. 2024 Mar; 25 (2): 327–332.Lajevardi V., Hosseini ZSS, Heidari S. Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double-blinded randomized controlled trial. Photodermatol Photoimmunol Photomed. 2023 Nov; 39 (6): 657–662.Lajevardi V., Hosseini ZSS, Heidari S. Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double-blinded randomized controlled trial. Photodermatol Photoimmunol Photomed. 2023 Nov; 39 (6): 657–662.Mehta H., Kumar S., Parsad D., Bishnoi A., Vinay K., Kumaran M. S. Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial. Dermatol Ther. 2021 Sep; 34 (5): e15033.Mehta H., Kumar S., Parsad D., Bishnoi A., Vinay K., Kumaran M. S. Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial. Dermatol Ther. 2021 Sep; 34 (5): e15033.Lu H., Xu J, Xie B., Hu Y., Luo H., Chen Y., Song X. The multi-target mechanism of Cyclosporin A in the treatment of vitiligo based on network pharmacology. Dermatol Ther. 2021 Jul; 34 (4): e15023.Lu H., Xu J, Xie B., Hu Y., Luo H., Chen Y., Song X. The multi-target mechanism of Cyclosporin A in the treatment of vitiligo based on network pharmacology. Dermatol Ther. 2021 Jul; 34 (4): e15023.Jawade S., Saoji V., Madke B., Singh A. Comparison of Oral Azathioprine and Oral Mini Pulse Steroid in the Treatment of Vitiligo: An Open-Label Randomized Controlled Trial. Indian J Dermatol. 2023 Nov-Dec; 68 (6): 591–597.Jawade S., Saoji V., Madke B., Singh A. Comparison of Oral Azathioprine and Oral Mini Pulse Steroid in the Treatment of Vitiligo: An Open-Label Randomized Controlled Trial. Indian J Dermatol. 2023 Nov-Dec; 68 (6): 591–597.Poolsuwan P., Churee C., Pattamadilok B. Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study. Photodermatol Photoimmunol Photomed. 2021 Mar; 37 (2): 123–130.Poolsuwan P., Churee C., Pattamadilok B. Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study. Photodermatol Photoimmunol Photomed. 2021 Mar; 37 (2): 123–130.Li C., Hu Y., Mu Z., Shi L., Sun X., Wang X., Wang Y., Li X. Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis. J Dermatolog Treat. 2024 Dec; 35 (1): 2302064.Li C., Hu Y., Mu Z., Shi L., Sun X., Wang X., Wang Y., Li X. Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis. J Dermatolog Treat. 2024 Dec; 35 (1): 2302064.Jin R., Hong W., Ye Z., Fu L., Hu W., Xu A. Comparative outcomes of autologous cultured melanocytes transplantation and non-cultured epidermal cell suspension transplantation in piebaldism patients: A retrospective study. Skin Res Technol. 2024 Jan;30 (1): e13580.Jin R., Hong W., Ye Z., Fu L., Hu W., Xu A. Comparative outcomes of autologous cultured melanocytes transplantation and non-cultured epidermal cell suspension transplantation in piebaldism patients: A retrospective study. Skin Res Technol. 2024 Jan;30 (1): e13580.Yousif J., Ceresnie M. S., Hamzavi I. H., Mohammad T. F. Practical guidelines for the treatment of vitiligo with the melanocyte-keratinocyte transplantation procedure. Arch Dermatol Res. 2023 Dec 1; 316 (1): 10.Yousif J., Ceresnie M. S., Hamzavi I. H., Mohammad T. F. Practical guidelines for the treatment of vitiligo with the melanocyte-keratinocyte transplantation procedure. Arch Dermatol Res. 2023 Dec 1; 316 (1): 10.Grimes P.E., Nashawati R. Depigmentation Therapies for Vitiligo. Dermatol Clin. 2017 Apr; 35 (2): 219–227.Grimes P.E., Nashawati R. Depigmentation Therapies for Vitiligo. Dermatol Clin. 2017 Apr; 35 (2): 219–227.Białczyk A, Wełniak A, Kamińska B, Czajkowski R. Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review. Mol Diagn Ther. 2023 Nov;27(6):723–739. doi: 10.1007/s40291–023–00672-z. Epub 2023 Sep 22. PMID: 37737953; PMCID: PMC10590312.Białczyk A, Wełniak A, Kamińska B, Czajkowski R. Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review. Mol Diagn Ther. 2023 Nov;27(6):723–739. doi: 10.1007/s40291–023–00672-z. Epub 2023 Sep 22. PMID: 37737953; PMCID: PMC10590312.Liu L.Y., Strassner J.P., Refat M.A., Harris J.E., King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017; 77 (4): 675–682Liu L.Y., Strassner J.P., Refat M.A., Harris J.E., King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017; 77 (4): 675–682Xu Z., Xing X., Xuan Y., Xiang L.F., Zhang C. Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow-band UVB: A case report of 2-year follow-up. Photodermatol Photoimmunol Photomed. 2023 Nov; 39 (6): 663–666.Xu Z., Xing X., Xuan Y., Xiang L.F., Zhang C. Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow-band UVB: A case report of 2-year follow-up. Photodermatol Photoimmunol Photomed. 2023 Nov; 39 (6): 663–666.Li X, Sun Y, Du J, Wang F, Ding X. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy. Clin Cosmet Investig Dermatol. 2023 Mar 11; 16: 635–638.Li X, Sun Y, Du J, Wang F, Ding X. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy. Clin Cosmet Investig Dermatol. 2023 Mar 11; 16: 635–638.Ireland P. A., Jansson N., Spencer SKR, Braden J., Sebaratnam D. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials. JAMA Dermatol. 2024 Jan 31: e235509.Ireland P. A., Jansson N., Spencer SKR, Braden J., Sebaratnam D. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials. JAMA Dermatol. 2024 Jan 31: e235509.

The authors declare that there are no conflicts of interest present.